Overview of current systemic management of EGFR-mutant NSCLC
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs. Other rare side-effects, such as hepatic impairment and interstitial lung disease, should be identified early and managed carefully. Patients with uncommon EGFR mutations, such as G719X, S768I, and L861Q, may require special selection of EGFR TKIs. The combination of erlotinib plus bevacizumab has been accepted in certain parts of the world as an alternative front-line treatment. This review article summarizes the studies leading to the establishment of EGFR TKIs in EGFR-mutant lung cancer patients. The side-effect profiles of the current EGFR TKIs in these large trials are listed, and the management of uncommon EGFR mutations is discussed. Finally, the potential role of combination front-line treatment is discussed.
著者Hsu WH, Yang JCH, Mok TS, Loong HH
期刊名稱Annals of Oncology
出版年份2018
月份1
卷號29
期次Supp 1
出版社OXFORD UNIV PRESS
出版地England
頁次i3 - i9
國際標準期刊號0923-7534
電子國際標準期刊號1569-8041
語言英式英語
關鍵詞non-small cell lung cancer, epidermal growth factor receptor
Web of Science 學科類別Oncology;Oncology

上次更新時間 2020-06-08 於 03:33